PT  - JOURNAL ARTICLE
AU  - Rhodes, Catherine
AU  - Harris, John
AU  - Sulston, John
AU  - Spanswick, Catherine
TI  - Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
AID  - 10.1136/medethics-2011-100032
DP  - 2012 Mar 01
TA  - Journal of Medical Ethics
PG  - 187--189
VI  - 38
IP  - 3
4099  - http://jme.bmj.com/content/38/3/187.short
4100  - http://jme.bmj.com/content/38/3/187.full
SO  - J Med Ethics2012 Mar 01; 38
AB  - There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future.